Figures & data
Table 1 Baseline characteristics of the study population
Figure 1 Proportion of patients without any EQ-5D complaints during the course of 12 weeks of strong opioid treatment (n=901 patients).
Table 2 Occurrence of pain-related complaints
Figure 2 Physicians’ assessment of overall quality of life, treatment tolerability, and compliance after 12 weeks of strong opioid treatment (n=901 patients; LOCF).
Figure 3 Weighted EQ-5D index scores (+ 95% confidence intervals) over the 12-week treatment period (morphine n=300, oxycodone n=300, oxycodone/naloxone n=301).
Figure 4 Proportion of patients without any EQ-5D complaints after 12 weeks of opioid treatment (morphine n=300, oxycodone n=300, oxycodone/naloxone n=301).
Figure 5 Relative changes to baseline in the QLIP sum score over the treatment period (morphine n=300, oxycodone n=300, oxycodone/naloxone n=301).
Abbreviations: BL, baseline; W, week; LOCF, last observation carried forward; QLIP, quality of life impairment by pain inventory; CI, confidence interval.
Table 3 Number of patients with improved quality of life after 12 weeks of opioid treatment (n=901 patients) as assessed by QLIP
Figure 6 Changes in the SF-12 physical (A) and mental (B) component scores over 12 weeks of treatment with oxycodone/naloxone (n=301), oxycodone (n=300), or morphine (n=300).
Abbreviations: BL, baseline; W, week; LOCF, last observation carried forward; SF, Short Form; CI, confidence interval.
Table 4 Number of patients with “good” or “very good” ratings for different treatment aspects after 12 weeks of opioid treatment as assessed by the treating physicians (n=901 patients)